Danish DMA reallocates competent authority duty
This article was originally published in Clinica
Executive Summary
The Danish Medicines Agency (DMA) has reallocated the competent authority role for medical devices between its divisions. The main agency role, including applications for and approval of clinical trials for medical devices, will now be dealt with by the consumer safety division, headed by Elen Andersen. All inspectorate-type activities will be handled by the inspection, laboratories and enforcement division, under Anne-Marie Vangsted, including inspections required for clinical trials. The reorganisation effectively separates off the inspectorate and enforcement authority for drugs and devices from all the other regulatory responsibilities undertaken by the authority.
You may also be interested in...
MoCRA Stakeholders Reminded Registration Enforcement Begins 1 July: ‘Do Not Delay!’
The Independent Beauty Association urged stakeholders at its Cosmetic Convergence Symposium to take action to ensure they are meeting requirements of the Modernization of Cosmetics Regulation Act come 1 July, when FDA’s enforcement of the facility and product registration deadline begins. Presenters offered tips from companies that have already completed the process.
Boehringer Ingelheim Overtakes Bayer As Germany’s Biggest Pharma Company
The privately owned company is searching for a successor to Jardiance, while the outcome of US Inflation Reduction Act talks on price cuts to the blockbuster will be revealed in September.
Synthekine Joins Quest To Tame IL-2 In Cancer Therapies
First clinical data from Synthekine’s IL-2 candidate and that ofrivalsMedicennawere presented at the AACR, suggesting there’s life in the modality yet.